Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins
- PMID: 1966810
Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins
Abstract
It has recently been demonstrated that very low concentrations of platelet-activating factor (PAF) and various cytokines can prime human neutrophils (PMN) to respond in an enhanced manner to subsequent agonistic stimulation. We were interested to ascertain whether superoxide generation by human PMN could be amplified by PAF following initial stimulation with tumor necrosis factor (TNF) and the effect of cholera and pertussis toxin on this process. PAF alone (0.1 pM-0.1 nM) failed to evoke any superoxide production; however, when PAF was added for 10 min to cells previously incubated for 50 min with 10 ng/ml TNF, superoxide production was significantly enhanced relative to that induced by TNF alone. Maximum amplification (+30%) was obtained with 10(-12) M PAF, this effect being completely abolished by BN 52021 and BN 52111, two structurally unrelated PAF antagonists. The PAF antagonists also decreased by 25% the superoxide production elicited solely by TNF, indicating that TNF-induced superoxide generation is partially mediated by a mechanism involving endogenous PAF. Pretreatment of the PMN with pertussis or cholera toxin reduced the amplification of superoxide production induced by PAF in TNF-stimulated PMN, implicating pertussis and cholera toxin-sensitive G-proteins in the amplification process.
Similar articles
-
Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins.Lipids. 1991 Dec;26(12):1071-5. doi: 10.1007/BF02536504. Lipids. 1991. PMID: 1668107
-
Cooperation between tumor necrosis factor (TNF) and platelet-activating factor (PAF) in the inflammatory response.J Lipid Mediat. 1990;2 Suppl:S151-9. J Lipid Mediat. 1990. PMID: 1966813
-
Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes.Biochem Biophys Res Commun. 1987 Nov 13;148(3):1412-7. doi: 10.1016/s0006-291x(87)80289-9. Biochem Biophys Res Commun. 1987. PMID: 2825685
-
Neutrophils accentuate renal cold ischemia-reperfusion injury. Dose-dependent protective effect of a platelet-activating factor receptor antagonist.J Pharmacol Exp Ther. 1997 Feb;280(2):786-94. J Pharmacol Exp Ther. 1997. PMID: 9023292
-
The role of platelet-activating factor (PAF) in interstitial pulmonary disease.J Investig Allergol Clin Immunol. 1994 May-Jun;4(3):149-57. J Investig Allergol Clin Immunol. 1994. PMID: 7981886 Review.
Cited by
-
Toxins-useful biochemical tools for leukocyte research.Toxins (Basel). 2010 Apr;2(4):428-52. doi: 10.3390/toxins2040428. Epub 2010 Mar 26. Toxins (Basel). 2010. PMID: 22069594 Free PMC article. Review.
-
Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits.Clin Exp Immunol. 1992 May;88(2):318-23. doi: 10.1111/j.1365-2249.1992.tb03080.x. Clin Exp Immunol. 1992. PMID: 1315229 Free PMC article.
-
PAF. A review of its effects, antagonists and possible future clinical implications (Part II).Drugs. 1991 Aug;42(2):174-204. doi: 10.2165/00003495-199142020-00002. Drugs. 1991. PMID: 1717219 Review. No abstract available.